Latest news

• Developers of COVID-19 vaccines and therapeutics highlight continued need for treatments

  In Q1, Regeneron recorded US net sales of $262m for REGEN-COV under its first contract with the US government.

• BioNTech on course to produce three billion doses of Pfizer-partnered COVID-19 vaccine in 2021

  In March, BioNTech forecast significant sales of 9.8bn for its Pfizer-partnered COVID-19 vaccine in 2021. ... The pharma giant revealed that the vaccine brought in global revenues of $3.5bn during Q1, forecasting that it now expects sales of the jab to

• Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales

  Overall, Pfizer’s Q1 revenues totalled $14.6bn, a 45% increase on the same period last year, reflecting an operational growth of $2.2bn or 42%. ... Although most of this growth was driven by BNT162b2, Pfizer also reported an increase in Q1 2021 sales

• Gilead’s Q1 revenues lifted by COVID-19 med Veklury as HIV drugs take a hit

  Total product sales excluding Veklury dropped by 11% to $4.9bn compared to Q1 2020. ... Overall, HIV product sales decreased by 12% to $3.7bn for the first quarter, although sales of its newer HIV treatment Biktarvy increased by 8% year-on-year in Q1.

• AstraZeneca reports ‘strong’ Q1 results, forecasts accelerated growth in 2021

  AstraZeneca has reported ‘solid’ first quarter results, as sales of its COVID-19 vaccine take off and the company’s oncology drugs deliver strong growth. ... Out of those sales, new medicines represented 53% of total revenue globally, compared to 47